Skip to main content
RXST logo

RXST · RxSight, Inc. · Financials

Track RXST — free
$4.77 -0.13 (-2.65%) Q2 2026 earnings call transcript
Market Cap
$201.73M
Shares
41.59M
Volume · Oct 28 291.44K Avg daily vol (3M) 790.68K

Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.

Revenue
$134.48M -3.9%
FY2025 Revenue FY2020–FY2025
Net Income
-$38.94M -41.8%
FY2025 Net Income FY2020–FY2025
Gross Margin
76.6% +5.9pp
FY2025 Gross Margin FY2020–FY2025
Operating Margin
-35.84% -9.5pp
FY2025 Operating Margin FY2020–FY2025
Diluted EPS
-$0.95 -33.8%
FY2025 Diluted EPS FY2020–FY2025
Operating Cash Flow
-$15.51M +8.5%
FY2025 Operating Cash Flow FY2020–FY2025

Chart any reported metric, KPI or segment over time — the full statement history lives here

Line Item FY2026 (G) TTM FY2025 FY2024 FY2023 FY2022 FY2021 FY2020
$140M – $160M $127.58M $134.48MG $139.93MG $89.08MG $49.01MG $22.59MG $14.68M
— $28.71M $31.47M $40.98M $35.31M $27.68M $18.08M $12.97M
— $98.87M $103.01M $98.94M $53.77M $21.33M $4.52M $1.71M
— — 76.6% 70.71% 60.36% 43.52% 19.99% 11.62%
— $36.67M $38.55M $34.37M $29.05M $25.98M $24.5M $21.93M
— $117.31M $112.65M $101.43M $74.8M $58.67M $32.81M $15.18M
— $3.54M $3.27M $3.58M $4.08M $3.88M $3.98M $3.85M
— $153.4M $151.2M $135.8M $103.85M $84.65M $57.3M $37.12M
— -$55.11M -$48.19M -$36.86M -$50.09M -$63.32M -$52.79M -$35.41M
— — -35.84% -26.34% -56.23% -129.21% -233.64% -241.26%
— -$51.58M -$44.93M -$33.28M -$46.01M -$59.43M -$48.81M -$31.56M
— $14K $19K $21K $3.31M $4.95M $3.68M $510K
— -$46.84M -$38.88M -$27.41M -$48.59M -$66.75M -$48.68M $27.63M
— $110K $66K $50K $20K $9000 $8000 $57K
— -$46.95M -$38.94M -$27.46M -$48.61M -$66.76M -$48.69M $27.58M
— — -28.96% -19.62% -54.57% -136.22% -215.5% 187.87%
— — — — — — -$48.69M $3.37M
— -$46.89M -$39.06M -$27.28M -$48.52M -$66.83M -$48.71M $27.53M
USD/shares — -$1.13 -$0.95 -$0.71 -$1.41 -$2.41 -$3.57 $0.91
USD/shares — -$1.13 -$0.95 -$0.71 -$1.41 -$2.41 -$3.57 $0.15
shares — — 40.85M 38.87M 34.46M 27.66M 13.63M 3.71M
shares — — 40.85M 38.87M 34.46M 27.66M 13.63M 5.53M
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.

Debt Profile

Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.

Reported debt balances

Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.

Reported balanceAs ofAmountSource
Finance lease liabilities 2026-06-30 USD 80,000 10-Q filed 2026-08-05
Related accounting measures — not additional borrowing

Carrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year.

Current finance lease liabilities
USD 31,000
Noncurrent finance lease liabilities
USD 49,000
Operating lease liabilities 2026-06-30 USD 10,500,000 10-Q filed 2026-08-05
Related accounting measures — not additional borrowing

Carrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year.

Current operating lease liabilities
USD 1,633,000
Noncurrent operating lease liabilities
USD 8,867,000
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.

Covenants

Covenant terms have not yet been verified for this profile.

The balance figures do not establish whether covenants apply or whether the company complies with them.

Loans, facilities and notes

The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.

Price & Valuation

Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.

Valuation

EV/Revenue
—
Peer median 2.08×
EV/EBIT
—
Peer median 19.09×
P/E (TTM)
—
Peer median 27.70×

Peer medians compare against the 81 similar-size Medical Devices companies (of 156 listed).

Valuation over time computed as of each quarter's filing date

Revenue Breakdown

Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.

Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.

By Product & Service (USD)

Component FY2025 FY2024 FY2023 FY2022 FY2021 FY2020
Rxlal $108,062,000 $96,497,000 $54,092,000 $24,965,000 — $4,256,000
LDD $20,669,000 $39,704,000 $32,091,000 $22,515,000 $13,774,000 $10,159,000
Service Warranty Service Contracts and Accessories $5,748,000 $3,726,000 $2,894,000 $1,525,000 $656,000 $263,000
Additions During the Period — — — — $793,000 —
Balance at Beginning of Period — — — — $540,000 $345,000
Balance at End of Period — — — — $540,000 —
LAL — — — — $8,163,000 —
Revenue Recognized During the Period — — — — -$598,000 —
Key facts CIK 1111485 CUSIP 78349D107 13F (30d) 17 filings 17 filers Visit website Investor relations